

Live, attenuated Nobivac® Tricat  
provides earlier onset of immunity  
than any other feline vaccine



the future of vaccination



# The importance of early protection in kittens

The feline diseases that we commonly vaccinate against present their greatest threat to the young; particularly once maternally-derived antibody (MDA) has fallen to non-protective levels.

Shortening the 'immunity gap' – the time between the decline of MDA and the onset of vaccine-derived immunity – is therefore vital, if we are to optimise protection.

An inspection of data sheets shows that Nobivac Tricat has the earliest stated onset of immunity of any core cat vaccine. And unlike some other vaccines, Nobivac Tricat has a data sheet claim that it is effective in the face of MDA levels likely to be encountered in the field.

# Onset of immunity at 7 days

Nobivac Tricat can be given in two doses, at 9 and 12 weeks of age, with immunity achieved by 13 weeks. This is the earliest recognised onset of any injectable feline vaccine. Onset of immunity for some other vaccines is not indicated, while for others, the onset for cat 'flu components can be as long as 4 weeks.


## FCV challenge trial in the face of MDA

Nobivac Tricat's efficacy in the face of MDA is important in ensuring early protection. The ability of the live F9 strain to stimulate immunity in the face of MDA was recently demonstrated in a challenge trial.

MDA-positive kittens were vaccinated between 7 and 9 weeks of age; followed by a second vaccination 3 weeks later. One month after the second vaccination, the kittens were challenged with a heavy dose of FCV, as were the unvaccinated controls (figure 1).

All vaccinates developed SN titres after vaccination, and compared to control cats had significantly reduced clinical scores following virulent challenge.

**Figure1. Clinical scores in kittens after virulent FCV challenge one month after completion of primary vaccination course in 9 vaccinated and 10 control kittens**



# Conclusion: the benefits of using live vaccines

The potential benefits of using attenuated rather than inactivated vaccines are well recognised in canine viral diseases. Similar principles apply to feline vaccines.

Classical understanding of immunity suggests that live vaccines mimic natural exposure. Potentially, they may therefore stimulate a broader and more rapid cell-mediated immunity (CMI) than traditional inactivated products.

Besides the prevention of clinical signs, CMI has important implications for the degree of persistence of the immune response, the young animal's ability to overcome maternally-derived antibody, and the reduction of field virus shedding after challenge.

Nobivac Tricat is the UK's leading feline vaccine<sup>1</sup>, in which all the components are live attenuated strains. Its safety and efficacy have been demonstrated in numerous trials and through years of experience in the field.

# Nobivac Tricat

## The proven vaccine

- Nobivac Tricat is administered to more UK cats than any other vaccine<sup>2</sup>
- All-live attenuated components allow earlier stated onset of immunity than any other feline vaccine
- A non-adjuvanted vaccine with a safety record proven through years of use
- Fully licensed for combined use (mixing) with Nobivac® FeLV and Nobivac® Rabies
- Nobivac vaccines come with the UK's most comprehensive support package. Ask your Intervet Account Manager for details



Intervet UK Ltd, Walton Manor, Walton, Milton Keynes MK7 7AJ

For further information about Nobivac® Tricat,  
please contact your Intervet Account Manager,  
call the Veterinary Support Group on 01908 685685,  
or visit [www.intervet.co.uk](http://www.intervet.co.uk)

#### References

1. Porter. C.J, Radford. A.D, Gaskell. R.M, Ryvar. R. and Dawson S., Comparison of the ability of FCV vaccines to neutralise a panel of current UK feline calicivirus isolates. (BSAVA 2006 abstract submitted)
2. GfK data October 2005

